Anidulafungin description: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Anidulafungin}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ERAXIS (ANIDULAFUNGIN) INJECTION, POWDER, LYOPH...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ERAXIS (ANIDULAFUNGIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea | publisher = | date = | accessdate = }}</ref> | ==Description== | ||
ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. | |||
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-dihydroxy-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, ERAXIS for Injection contains the following inactive ingredients: | |||
50 mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. | |||
100 mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. | |||
The empirical formula of anidulafungin is C58H73N7O17 and the formula weight is 1140.3. | |||
The structural formula is: | |||
{| | |||
|[[File:DescribtionAnidulafungin.JPG|600px|thumb]] | |||
|} | |||
Prior to administration, ERAXIS for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline). | |||
'''DO NOT''' dilute with other solutions or co-infuse with other medications or electrolytes<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ERAXIS (ANIDULAFUNGIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a88d9010-55fb-4a02-baff-042cd27688ea | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 01:52, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Description
ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-dihydroxy-N2-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, ERAXIS for Injection contains the following inactive ingredients:
50 mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment.
100 mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment.
The empirical formula of anidulafungin is C58H73N7O17 and the formula weight is 1140.3.
The structural formula is:
 |
Prior to administration, ERAXIS for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline).
DO NOT dilute with other solutions or co-infuse with other medications or electrolytes[1]
References
Adapted from the FDA Package Insert.